Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Manca, Paolo, Russano, Marco, Pantano, Francesco, Tonini, Giuseppe, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601795/
https://www.ncbi.nlm.nih.gov/pubmed/28938699
http://dx.doi.org/10.18632/oncotarget.17607
Descripción
Sumario:We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, the switch to SCLC histotype occurred in the only site not responsive to afatinib and subsequently the most responsive to chemotherapy. Our case shows that occurrence of switch to SCLC is a possible mechanism of resistance during treatment with Afatinib.

Ejemplares similares